Frequently Asked Questions about Vir Biotechnology, Inc. (VIR)

Name: Vir Biotechnology, Inc. (VIR) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Vir Biotechnology, Inc. (VIR) do?

Accepted Answer

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for ...

Question 2

Is Vir Biotechnology, Inc. (VIR) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of VIR reveals an Altman Z-Score of 1.34 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.07B most recent), help investors decide if VIR fits their risk profile.

Question 3

What is the current P/E ratio for VIR?

Accepted Answer

As of the latest trading session, Vir Biotechnology, Inc. (VIR) has a trailing P/E ratio of -3.12.

Question 4

Who is the CEO of Vir Biotechnology, Inc.?

Accepted Answer

The current Chief Executive Officer of Vir Biotechnology, Inc. is Marianne De Backer.

Question 5

What was VIR's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Vir Biotechnology, Inc. reported annual revenues of $0.07B (2025), $0.07B (2024), $0.09B (2023), $1.62B (2022), $1.10B (2021) respectively.

Question 6

Does VIR pay a dividend?

Accepted Answer

Vir Biotechnology, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does VIR have?

Accepted Answer

In its latest reporting period, Vir Biotechnology, Inc. generated $-0.40B in Free Cash Flow against a total debt load of $0.19B.

Question 8

What is the Price-to-Book (P/B) ratio of Vir Biotechnology, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Vir Biotechnology, Inc. (VIR) is currently 1.79.

Question 9

What is the Price-to-Sales (P/S) ratio of VIR?

Accepted Answer

Based on trailing twelve-month data, Vir Biotechnology, Inc. (VIR) trades at a Price-to-Sales (P/S) ratio of 22.91.

Question 10

What is Vir Biotechnology, Inc.'s Return on Equity (ROE)?

Accepted Answer

Vir Biotechnology, Inc. (VIR) has a Return on Equity (ROE) of -49.31%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-391.8M	49.1M	-4.8M	-396.6M	-445.7M
2024-12	-446.4M	78.5M	-7.3M	-453.7M	-532.1M
2023-12	-778.8M	0	-21.6M	-800.4M	-800.4M
2022-12	1.7B	102.1M	-68M	1.6B	1.5B
2021-12	-47.6M	83.8M	-21.8M	-69.4M	-153.2M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-391.8M	49.1M	-4.8M	-396.6M	-445.7M
2024-12	-446.4M	78.5M	-7.3M	-453.7M	-532.1M
2023-12	-778.8M	0	-21.6M	-800.4M	-800.4M
2022-12	1.7B	102.1M	-68M	1.6B	1.5B
2021-12	-47.6M	83.8M	-21.8M	-69.4M	-153.2M